The pharmaceutical world has not seen a supply-demand imbalance quite like this in decades. GLP-1 receptor agonists, particularly semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) and tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly), have become the most sought-after medications on the planet. What began as a treatment for type 2 diabetes has expanded into weight management, cardiovascular risk reduction, and a growing list of potential new indications, creating a demand surge that has left global supply chains struggling to keep pace.
The Scale of the Shortage
The numbers tell a compelling story. Since 2023, demand for GLP-1 receptor agonists has grown by over 300%, driven by expanding approvals for weight loss indications and overwhelming patient interest. The FDA has maintained semaglutide and tirzepatide on its drug shortage list for extended periods, and patients worldwide have faced weeks-long waits for prescriptions. Healthcare providers report turning away patients or cycling through alternative dosage forms simply to maintain continuity of care.
This is not a temporary blip. Analysts project the global GLP-1 market could reach $150 billion by 2030, up from roughly $50 billion in 2025. New clinical data continues to emerge showing benefits for heart failure, kidney disease, sleep apnea, and even neurodegenerative conditions, each new indication adding millions of potential patients to the demand pool.
Manufacturing Investments by Originator Companies
Both Novo Nordisk and Eli Lilly have responded with historically large manufacturing investments. Novo Nordisk has committed over $18 billion to expanding production capacity across Denmark, France, and the United States. Eli Lilly has invested more than $12 billion in new manufacturing facilities in Indiana, North Carolina, and Ireland. These are multi-year construction projects, and even with aggressive timelines, full production capacity is not expected until 2028 or beyond.
The challenge is not simply building more factories. GLP-1 drugs are peptide-based biologics that require sophisticated manufacturing processes including solid-phase peptide synthesis, purification through high-performance liquid chromatography, and formulation into injectable delivery systems. Scaling these processes while maintaining stringent quality standards is fundamentally different from scaling small-molecule generic drug production.
What This Means for API Manufacturers in India
India’s pharmaceutical industry, long recognized as the pharmacy of the world for generic medicines, is watching the GLP-1 space with intense interest. Several Indian API manufacturers have already invested in peptide synthesis capabilities, and the current shortage creates both immediate and long-term opportunities.
In the near term, demand for peptide synthesis intermediates, excipients, and related raw materials has increased significantly. Companies with existing capabilities in peptide chemistry are finding new customers among contract development and manufacturing organizations (CDMOs) serving the GLP-1 pipeline. Longer term, as semaglutide patents begin expiring in certain markets starting in 2026, Indian manufacturers are positioning themselves to supply biosimilar versions of these blockbuster drugs.
India’s cost advantages in manufacturing, combined with a deep talent pool in chemistry and an established regulatory track record, make it a natural hub for GLP-1 API production. However, peptide manufacturing requires different equipment and expertise than traditional small-molecule synthesis, and companies will need to invest accordingly.
The Compounding Pharmacy Controversy
The shortage has also fueled a heated debate around compounded versions of GLP-1 drugs. Under FDA Section 503A and 503B, compounding pharmacies have been producing semaglutide and tirzepatide formulations to meet patient demand. This has created a parallel supply chain that operates under different regulatory oversight than commercially approved products.
Novo Nordisk and Eli Lilly have pushed back strongly, arguing that compounded versions pose safety risks and infringe on their intellectual property. The FDA has taken an evolving stance, initially allowing compounding during the shortage but signaling a tighter approach as originator supply improves. For international markets, this controversy highlights the tension between patient access and regulatory standards, a dynamic that pharmaceutical exporters must navigate carefully.
Impact on Global Pharmaceutical Trade
The GLP-1 crisis is reshaping pharmaceutical trade patterns in several important ways.
Supply chain diversification has become a top priority. The concentration of GLP-1 manufacturing capacity among just two companies has exposed the vulnerability of single-source dependency. Governments and healthcare systems are actively seeking to diversify their supply chains, creating openings for qualified manufacturers in India and other countries.
Peptide manufacturing investment is accelerating globally. Countries that previously had limited peptide production capabilities are now investing in this area, recognizing it as a strategic priority. India, China, South Korea, and several European nations have announced targeted funding programs for peptide manufacturing infrastructure.
Regulatory harmonization efforts have gained momentum. The need to rapidly qualify new manufacturing sites and approve biosimilar versions of GLP-1 drugs has highlighted inefficiencies in the current regulatory patchwork. Initiatives to harmonize approval pathways across major markets could significantly benefit Indian pharmaceutical exporters.
Cold chain infrastructure is receiving renewed attention. GLP-1 drugs require refrigerated storage and transport, and the scale of demand is straining existing cold chain networks. Exporters who invest in robust cold chain capabilities will have a competitive advantage as the market expands.
Future Outlook
The GLP-1 market is still in its early stages. Beyond the current approved indications for diabetes and obesity, clinical trials are exploring these drugs for Alzheimer’s disease, liver disease (MASH/NASH), polycystic ovary syndrome, addiction, and numerous other conditions. Each successful trial could add billions of dollars to the addressable market.
Oral formulations of GLP-1 drugs are also advancing through development. Novo Nordisk’s oral semaglutide (Rybelsus) has already been approved, and next-generation oral formulations with improved bioavailability are in late-stage trials. Oral delivery would dramatically expand patient access and further increase demand for API manufacturing capacity.
For Indian pharmaceutical companies, the opportunity extends beyond simply manufacturing biosimilar versions of existing drugs. The expertise developed in peptide synthesis, purification, and formulation can be applied across a growing family of peptide-based therapeutics. Companies that build strong capabilities now will be well-positioned for decades of growth.
Key Takeaways
- GLP-1 demand has grown over 300% since 2023, with the market projected to reach $150 billion by 2030
- Originator companies have committed over $30 billion in manufacturing expansion, but capacity constraints will persist through at least 2028
- Indian API manufacturers have a significant opportunity in peptide synthesis, both for intermediates today and biosimilar APIs in the coming years
- The compounding pharmacy controversy highlights the tension between patient access and regulatory oversight
- Supply chain diversification, cold chain investment, and regulatory harmonization are reshaping global pharmaceutical trade
- Companies that invest in peptide manufacturing capabilities now will be positioned for long-term growth across multiple therapeutic areas
The GLP-1 crisis is not just a temporary supply chain disruption. It represents a fundamental shift in pharmaceutical demand patterns that will influence manufacturing investment, trade relationships, and regulatory policy for years to come. At KP Life Science, we are closely monitoring these developments and working with our partners to ensure reliable supply of high-quality pharmaceutical products as this market continues to evolve.